Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for Blood Coagulants is appreciably influenced by the growing occurrence of hemostatic problems, which include hemophilia and von Willebrand ailment. The increasing occurrence of those conditions globally contributes to the developing demand for powerful blood coagulation treatment options. The demand for Blood Coagulants is driven by the widespread use of those sellers in surgical methods and trauma cases. Blood Coagulants play an essential function in stopping immoderate bleeding for the duration of surgical procedures and handling bleeding associated with annoying injuries, contributing to their large utility in healthcare settings. The worldwide demographic shift in the direction of a growing old population is a key component driving the Blood Coagulants market. Older individuals are extra at risk of hemostatic problems and might require blood coagulation aid, leading to expanded demand for these treatments as the elderly population continues to develop.
Cardiovascular diseases frequently require anticoagulant therapy to prevent blood clots and related complications. The growing occurrence of cardiovascular sicknesses globally contributes drastically to the demand for Blood Coagulants, particularly anticoagulant medicines. Blood coagulants are increasingly being explored for new warning signs beyond conventional uses. Research and development efforts are cognizant of expanding the therapeutic packages of Blood Coagulants to cope with a wider variety of situations, similarly using market increase.
The evolving healthcare landscape emphasizes patient-centric approaches, influencing the improvement of Blood Coagulants. Therapies that offer stepped-forward comfort, reduced aspect effects, and stronger affected person adherence contribute to the market's evolution, aligning with the wider goals of affected person satisfaction and consequences. Collaborations and partnerships between pharmaceutical businesses, study establishments, and healthcare agencies play a pivotal role in advancing Blood Coagulants. These partnerships foster research, improvement, and the commercialization of revolutionary coagulation treatments, shaping the aggressive panorama. Stringent regulatory requirements and help for the development of safe and effective Blood Coagulants influence market dynamics. Regulatory approvals and compliance with established hints are vital for gaining acceptance as true with healthcare professionals and making sure of the successful introduction of recent coagulation merchandise to the market.
Blood Coagulants Market Highlights:
Middle East & Africa Blood Coagulants Market Overview
The Middle East & Africa Blood Coagulants Market is expected to grow USD 2.77 Billion at a CAGR 6.70% during the forcast period 2023 to 2030.Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding. The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders.Â
In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients
The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.
Figure- MEA blood coagulants market, by Country 2016 (%) 
Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR AnalysisÂ
Intended Audience:
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential InvestorsÂ
Research Methodology:
Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR AnalysisÂ
Segmentation  Â
The Middle East & Africa blood coagulants market is segmented on the basis of types, indications, and by country.
On the basis of types, the Middle East & Africa blood coagulants market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.
On the basis of indication, the Middle East & Africa blood coagulants market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.
On the basis of country, the Middle East & Africa blood coagulants market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa.Â
Regional Analysis
The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country.Â
Key Findings:
- Hemophilia segment dominates the market with nearly 45.5% share of the MEA market
- MEA coagulation factor market is projected to reach about USD 141.68 million by 2023
- MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016
- UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023
Key Players for Middle East & Africa blood coagulants market
Some of the major players in Middle East & Africa blood coagulants market are: Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
